A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-4)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Dec 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Baricitinib (Primary) ; Dexamethasone (Primary) ; Remdesivir (Primary)
Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
Focus Therapeutic Use
Acronyms ACTT-4

29 Nov 2022 Results post hoc of analysis compared recovery and mortality between these comparable sequential cohorts of patients who received remdesivir plus SOC, adjusting for baseline characteristics with propensity score weighting published in the Annals of Internal Medicine
04 Oct 2022 Results published in the Annals of Internal Medicine
16 Nov 2021 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com